Already a member? Log in

Sign up with your...


Sign Up with your email address

Add Tags

Duplicate Tags

Rename Tags

Share This URL With Others!

Save Link

Sign in

Sign Up with your email address

Sign up

By clicking the button, you agree to the Terms & Conditions.

Forgot Password?

Please enter your username below and press the send button.
A password reset link will be sent to you.

If you are unable to access the email address originally associated with your Delicious account, we recommend creating a new account.

Links 1 through 2 of 2 by Charlie Schick tagged netezza

"Some members of the advisory committee pointed to a downside in today's decision to strip the drug of its breast cancer label: This could undermine the accelerated approval process under which Avastin first got FDA's blessing. Accelerated approval is a way to get drugs to the sickest patients more quickly, with less clinical data. It's virtually unheard of for FDA to reverse such an approval. In this case, FDA did so, agency officials said, after subsequent studies showed that the benefit was much less than initially thought."

I've been following pharmacoepidemiology quite a lot lately, mostly because one of the product we sell (and I market) is used to look the effectiveness of drugs, help understand if there might be some off-label uses, and help drugs like Avastin succeed in their selected market and others that might also work. Of course, I'm now going to see how this deregulation can be avoided with better data analysis.

Share It With Others!

"I've pulled out from Baum's comments a range of timely ideas that help bring some perspective to the rapidly evolving and often-intersecting areas of data warehousing, purpose-built appliances, business analytics, Big Data, and how companies are trying to leverage all of that to turn insight into foresight."

Share It With Others!